Neuropace Stock Performance
| NPCE Stock | USD 13.56 0.45 3.21% |
The company secures a Beta (Market Risk) of 1.58, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Neuropace will likely underperform. Neuropace has an expected return of -0.0223%. Please make sure to verify Neuropace kurtosis, as well as the relationship between the rate of daily change and market facilitation index , to decide if Neuropace performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Neuropace has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound fundamental indicators, Neuropace is not utilizing all of its potentials. The newest stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
Actual Historical Performance (%)
One Day Return (3.80) | Five Day Return (5.33) | Year To Date Return 33.38 | Ten Year Return (47.74) | All Time Return (47.74) |
1 | Sale by Martha Morrell of 11262 shares of Neuropace | 02/01/2024 |
2 | Sale by Martha Morrell of 14143 shares of Neuropace | 02/06/2024 |
3 | Acquisition by Rebecca Kuhn of 12500 shares of Neuropace subject to Rule 16b-3 | 02/28/2024 |
4 | Conversion by Orbimed Advisors Llc of 3605386 shares of Neuropace | 02/29/2024 |
5 | NeuroPace, Inc. Q4 2023 Earnings Call Transcript | 03/07/2024 |
6 | The Latest Analyst Ratings For NeuroPace - NeuroPace - Benzinga | 03/12/2024 |
7 | NeuroPace, Inc. Receives Average Recommendation of Moderate Buy from Brokerages - MarketBeat | 03/20/2024 |
8 | Citigroup Inc. Takes Position in NeuroPace, Inc. - Defense World | 04/03/2024 |
9 | Disposition of 461899 shares by Orbimed Advisors Llc of Neuropace at 14.49 subject to Rule 16b-3 | 04/11/2024 |
10 | OrbiMed Advisors sells over 7 million in NeuroPace stock | 04/15/2024 |
11 | Disposition of 14069 shares by Orbimed Advisors Llc of Neuropace at 14.01 subject to Rule 16b-3 | 04/16/2024 |
12 | Disposition of 300 shares by Orbimed Advisors Llc of Neuropace at 14.15 subject to Rule 16b-3 | 04/17/2024 |
13 | Disposition of 18253 shares by Orbimed Advisors Llc of Neuropace at 14.02 subject to Rule 16b-3 | 04/19/2024 |
14 | Disposition of 24609 shares by Orbimed Advisors Llc of Neuropace at 14.05 subject to Rule 16b-3 | 04/22/2024 |
15 | Disposition of 21791 shares by Orbimed Advisors Llc of Neuropace at 14.29 subject to Rule 16b-3 | 04/23/2024 |
| Begin Period Cash Flow | 6.6 M |
Neuropace |
Neuropace Relative Risk vs. Return Landscape
If you would invest 1,457 in Neuropace on January 26, 2024 and sell it today you would lose (101.00) from holding Neuropace or give up 6.93% of portfolio value over 90 days. Neuropace is currently does not generate positive expected returns and assumes 4.3534% risk (volatility on return distribution) over the 90 days horizon. In different words, 38% of stocks are less volatile than Neuropace, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Neuropace Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Neuropace's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Neuropace, and traders can use it to determine the average amount a Neuropace's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0051
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | NPCE |
Estimated Market Risk
| 4.35 actual daily | 38 62% of assets are more volatile |
Expected Return
| -0.02 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Neuropace is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Neuropace by adding Neuropace to a well-diversified portfolio.
Neuropace Fundamentals Growth
Neuropace Stock prices reflect investors' perceptions of the future prospects and financial health of Neuropace, and Neuropace fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Neuropace Stock performance.
| Return On Equity | -1.19 | ||||
| Return On Asset | -0.15 | ||||
| Profit Margin | (0.50) % | ||||
| Operating Margin | (0.28) % | ||||
| Current Valuation | 390.29 M | ||||
| Shares Outstanding | 28.72 M | ||||
| Price To Book | 18.44 X | ||||
| Price To Sales | 5.85 X | ||||
| Revenue | 65.42 M | ||||
| Gross Profit | 32.49 M | ||||
| EBITDA | (25.57 M) | ||||
| Net Income | (32.96 M) | ||||
| Cash And Equivalents | 92.41 M | ||||
| Cash Per Share | 3.72 X | ||||
| Total Debt | 72.39 M | ||||
| Debt To Equity | 1.08 % | ||||
| Current Ratio | 9.86 X | ||||
| Book Value Per Share | 0.74 X | ||||
| Cash Flow From Operations | (19.7 M) | ||||
| Earnings Per Share | (1.27) X | ||||
| Market Capitalization | 376.23 M | ||||
| Total Asset | 107.65 M | ||||
| Retained Earnings | (503.81 M) | ||||
| Working Capital | 76.49 M | ||||
About Neuropace Performance
To evaluate Neuropace Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Neuropace generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Neuropace Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Neuropace market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Neuropace's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 236.61 | 276.82 | |
| Return On Tangible Assets | (0.31) | (0.32) | |
| Return On Capital Employed | (0.30) | (0.31) | |
| Return On Assets | (0.31) | (0.32) | |
| Return On Equity | (1.60) | (1.52) |
Things to note about Neuropace performance evaluation
Checking the ongoing alerts about Neuropace for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Neuropace help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Neuropace generated a negative expected return over the last 90 days | |
| Neuropace has high historical volatility and very poor performance | |
| Neuropace has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 65.42 M. Net Loss for the year was (32.96 M) with profit before overhead, payroll, taxes, and interest of 32.49 M. | |
| Neuropace currently holds about 92.41 M in cash with (19.7 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.72. | |
| Neuropace has a frail financial position based on the latest SEC disclosures | |
| Over 78.0% of the company shares are owned by institutional investors | |
| Latest headline from investing.com: Disposition of 21791 shares by Orbimed Advisors Llc of Neuropace at 14.29 subject to Rule 16b-3 |
- Analyzing Neuropace's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Neuropace's stock is overvalued or undervalued compared to its peers.
- Examining Neuropace's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Neuropace's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Neuropace's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Neuropace's stock. These opinions can provide insight into Neuropace's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neuropace. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Neuropace Stock refer to our How to Trade Neuropace Stock guide.Note that the Neuropace information on this page should be used as a complementary analysis to other Neuropace's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Complementary Tools for Neuropace Stock analysis
When running Neuropace's price analysis, check to measure Neuropace's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuropace is operating at the current time. Most of Neuropace's value examination focuses on studying past and present price action to predict the probability of Neuropace's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neuropace's price. Additionally, you may evaluate how the addition of Neuropace to your portfolios can decrease your overall portfolio volatility.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Stocks Directory Find actively traded stocks across global markets |
Is Neuropace's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuropace. If investors know Neuropace will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuropace listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.27) | Revenue Per Share 2.531 | Quarterly Revenue Growth 0.408 | Return On Assets (0.15) | Return On Equity (1.19) |
The market value of Neuropace is measured differently than its book value, which is the value of Neuropace that is recorded on the company's balance sheet. Investors also form their own opinion of Neuropace's value that differs from its market value or its book value, called intrinsic value, which is Neuropace's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuropace's market value can be influenced by many factors that don't directly affect Neuropace's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neuropace's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuropace is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuropace's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.